- Home
- WHF vs VNDA Comparison
WHF vs VNDA Comparison
Compare WHF & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHF
- VNDA
- Stock Information
- Founded
- WHF 2011
- VNDA 2002
- Country
- WHF United States
- VNDA United States
- Employees
- WHF N/A
- VNDA N/A
- Industry
- WHF Finance Companies
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- WHF Finance
- VNDA Health Care
- Exchange
- WHF Nasdaq
- VNDA Nasdaq
- Market Cap
- WHF 214.3M
- VNDA 237.9M
- IPO Year
- WHF 2012
- VNDA 2006
- Fundamental
- Price
- WHF $9.73
- VNDA $4.33
- Analyst Decision
- WHF Sell
- VNDA Strong Buy
- Analyst Count
- WHF 4
- VNDA 2
- Target Price
- WHF $10.83
- VNDA $16.50
- AVG Volume (30 Days)
- WHF 130.5K
- VNDA 754.6K
- Earning Date
- WHF 05-07-2025
- VNDA 05-07-2025
- Dividend Yield
- WHF 15.84%
- VNDA N/A
- EPS Growth
- WHF N/A
- VNDA N/A
- EPS
- WHF 0.47
- VNDA N/A
- Revenue
- WHF $92,817,000.00
- VNDA $198,772,000.00
- Revenue This Year
- WHF N/A
- VNDA $14.36
- Revenue Next Year
- WHF N/A
- VNDA $44.53
- P/E Ratio
- WHF $20.84
- VNDA N/A
- Revenue Growth
- WHF N/A
- VNDA 3.18
- 52 Week Low
- WHF $8.44
- VNDA $3.85
- 52 Week High
- WHF $13.44
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- WHF 54.38
- VNDA 43.42
- Support Level
- WHF $8.44
- VNDA $4.27
- Resistance Level
- WHF $9.20
- VNDA $4.46
- Average True Range (ATR)
- WHF 0.35
- VNDA 0.22
- MACD
- WHF 0.09
- VNDA 0.01
- Stochastic Oscillator
- WHF 94.85
- VNDA 54.55
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.